Mesoblast Limited announced that the Phase III trial of its allogeneic mesenchymal stem cell product candidate MSC-100-IV (remestemcel-L) in children...
Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older. IVEMEND 150 mg is given as part of a combination therapy (see section 4.2).